Use of tranexamic acid in primary hip arthroplasty: a retrospective audit of blood loss and transfusion rates
DOI:
https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20262014Keywords:
Anti-fibrinolytics, Blood saving measures, Haematocrit, Haemoglobin, Total hip arthroplasty, Tranexamic acidAbstract
Background: Tranexamic acid (TXA) is an anti-fibrinolytic agent that has shown promise in reducing blood loss during total hip arthroplasty (THA). Several studies have reported the significance of blood loss reduction and the reduction in the number of blood transfusions, thereby reducing transfusion- related injuries and enhancing patient recovery. The concern about the use of tranexamic acid is the venous thromboembolic effect it may possess. We aimed to study the efficacy and safety of this anti-fibrinolytic medication in primary total hip arthroplasty.
Methods: We conducted a retrospective chart review of 130 primary total hip arthroplasty (THA) performed from June 2023 to June 2025 at a single arthroplasty centre in South Korea by a single renowned arthroplasty surgeon. Surgical patients received 1 g intra-venous (IV) TXA half hour before the surgery followed by 2g intra-articular (IA) TXA during the surgery through a hemobag line. We analysed differences in haemoglobin (Hb), haematocrit (Hct), blood loss (BL), and adverse events in these patients.
Results: The mean age was 61.3 years, and the mean BMI was 21.5 kg/m². All patients received 3g TXA. The mean blood loss was 550 ml, and mean hemoglobin drop after surgery was 1.13 g/dl. Strong positive correlation was found between blood loss and transfusions (r=0.726, p<0.001). Twenty-one adverse events were reported.
Conclusions: Administration combined intravenous (IV) and intra-articular (IA) TXA does not appear to increase rates of adverse events and may be effective in minimizing blood loss, thereby minimizing the number of blood transfusions as reflected by Hb and Hct values following THA.
References
Hays MB, Mayfield JF. Total blood loss in major joint arthroplasty: a comparison of cemented and noncemented hip and knee operations. J Arthroplasty. 1988;3:S47-9.
Park JH, Kim HS, Yoo JH, Kim JH, Sung KH, Kim JY, et al. Perioperative blood loss in bipolar hemiarthroplasty for femoral neck fracture: analysis of risk factors. Hip Pelvis. 2013;25(2):110-4.
Donovan RL, Lostis E, Jones I, Whitehouse MR. Estimation of blood volume and blood loss in primary total hip and knee replacement: an analysis of formulae for perioperative calculations and their ability to predict length of stay and blood transfusion requirements. J Orthop. 2021;24:227-32.
Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, et al. Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet. 2011;378(9800):1396-407.
Vaglio S, Prisco D, Biancofiore G. Recommendations for the implementation of a patient blood management programme: application to elective major orthopaedic surgery in adults. Blood Transfus. 2016;14(1):23-65.
Spiess BD. Transfusion of blood products affects outcome in cardiac surgery. Semin Cardiothorac Vasc Anesth. 2004;8(4):267-81.
Rawn J. The silent risks of blood transfusion. Curr Opin Anaesthesiol. 2008;21(5):664-8.
Frisch NB, Wessell NM, Charters MA, Yu S, Jeffries JJ, Silverton CD. Predictors and complications of blood transfusion in total hip and knee arthroplasty. J Arthroplasty. 2014;29(9):189-92.
Bouras M, Bourdiol A, Rooze P, Hourmant Y, Caillard A, Roquilly A. Tranexamic acid: a narrative review of its current role in perioperative medicine and acute medical bleeding. Front Med (Lausanne). 2024;11:1416998.
Longstaff C, Kolev K. Basic mechanisms and regulation of fibrinolysis. J Thromb Haemost. 2015;13:S98-105.
Mannucci PM. Hemostatic drugs. N Engl J Med. 1998;339:245-53.
Lin H, Xu L, Yu S, Hong W, Huang M, Xu P. Therapeutics targeting the fibrinolytic system. Exp Mol Med. 2020;52:367-79.
Tieu BH, Holcomb JB, Schreiber MA. Coagulopathy: its pathophysiology and treatment in the injured patient. World J Surg. 2007;31(5):1055-64.
Yi Z, Bin S, Jing Y, Zongke Z, Pengde K, Fuxing P. Tranexamic acid administration in primary total hip arthroplasty: a randomized controlled trial of intravenous combined with topical versus single-dose intravenous administration. J Bone Joint Surg Am. 2016;98(11):983-91.
Chen JY, Chin PL, Moo IH, Pang HN, Tay DKJ, Chia SL, et al. Intravenous versus intra-articular tranexamic acid in total knee arthroplasty: a double-blinded randomized controlled noninferiority trial. Knee. 2016;23(1):152-6.
Melvin JS, Stryker LS, Sierra RJ. Tranexamic Acid in Hip and Knee Arthroplasty. J Am Acad Orthop Surg. 2015;23(12):732-40.
Zha GC, Zhu XR, Wang L, Li HW. Tranexamic acid reduces blood loss in primary total hip arthroplasty performed using the direct anterior approach: a one-center retrospective observational study. J Orthop Traumatol. 2022;23:12.
Saleh A, Small T, Chandran Pillai ALP, Schiltz NK, Klika AK, Barsoum WK. Allogenic blood transfusion following total hip arthroplasty: results from the nationwide inpatient sample, 2000 to 2009. J Bone Joint Surg Am. 2014;96(18):e155.
Risman RA, Kirby NC, Bannish BE, Hudson NE, Tutwiler V. Fibrinolysis: an illustrated review. Res Pract Thromb Haemost. 2023;7(2):100081.
Hays MB, Mayfield JF. Total blood loss in major joint arthroplasty. A comparison of cemented and noncemented hip and knee operations. J Arthroplasty. 1988;3(Suppl):S47–9.
Billote DB, Glisson SN, Green D, Wixson RL. A prospective, randomized study of preoperative autologous donation for hip replacement surgery. J Bone Joint Surg Am. 2002;84(8):1299-304.
Charrois O, Kahwaji A, Vastel L, Rosencher N, Courpied JP. Blood loss in total hip arthroplasty for rapidly destructive coxarthrosis. Int Orthop. 2001;25(1):22-4.
Akti S, Zeybek H, Bilekli AB, Çelebi NÖ, Erdem Y, Çankaya D. The effect of tranexamic acid on hidden blood loss in total hip arthroplasty. Jt Dis Relat Surg. 2022;33(1):102-8.
Zufferey PJ, Miquet M, Quenet S, Martin P, Adam P, Albaladejo P, et al. Tranexamic acid in hip fracture surgery: a randomized controlled trial. Br J Anaesth. 2010;104(1):23-30.
Sukeik M, Alshryda S, Haddad FS, Mason JM. Systematic review and meta-analysis of the use of tranexamic acid in total hip replacement. J Bone Joint Surg Br. 2011;93(1):39-46.
Fillingham YA, Ramkumar DB, Jevsevar DS, Yates AJ, Shores P, Mullen K, et al. The efficacy of tranexamic acid in total hip arthroplasty: a network meta-analysis. J Arthroplasty. 2018;33(10):3083-9.
Ghorbani M, Sadrian SH, Ghaderpanah R, Neitzke CC, Chalmers BP, Esmaeilian S, et al. Tranexamic acid in total hip arthroplasty: an umbrella review on efficacy and safety. J Orthop. 2024;54:90-102.
Thapaliya A, Mittal MM, Ratcliff TL, Mounasamy V, Wukich DK, Sambandam SN. Usage of tranexamic acid for total hip arthroplasty: a matched cohort analysis of 144,344 patients. J Clin Med. 2024;13(18):4920.
Tan Y, Wang X, Li J, Zhang Y, Liu Y, Chen Z, et al. Topical versus intravenous tranexamic acid in total hip arthroplasty: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2021;100(5):e24392.
Seo JG, Kim DH, Lee YS, Kim HJ, Park JH, Song EK. Comparison of topical and intravenous tranexamic acid in primary total hip arthroplasty. Bone Joint J. 2017;99(2):210-5.
Xu H, Li Y, Wang X, Zhang Y, Liu J, Chen Z, et al. Combined intravenous and topical administration of tranexamic acid in primary total hip arthroplasty. Medicine (Baltimore). 2019;98(15):e15166.
CRISTAL Trial Investigators. Effect of intravenous tranexamic acid on surgical bleeding in hip or knee arthroplasty: the CRISTAL randomized trial. N Engl J Med. 2022;386(20):1986-97.
Goodnough LT. Risks of blood transfusion. Anesthesiol Clin North Am. 2005;23(2):241-52.
Rawn J. The silent risks of blood transfusion. Curr Opin. Anaesthesiol. 2008;21:664-8.
Buerger CS, Jain H. Infectious complications of blood transfusion. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2025.
Hart A, Khalil JA, Carli A, Huk O, Zukor D, Antoniou J. Blood transfusion in primary total hip and knee arthroplasty: incidence, risk factors, and thirty-day complication rates. J Bone Joint Surg Am. 2014;96(23):1945-51.
Poeran J, Chan JJ, Zubizarreta N, Mazumdar M, Galatz LM, Moucha CS. Safety of Tranexamic Acid in Hip and Knee Arthroplasty in High-risk Patients. Anesthesiology. 2021;135(1):57-68.
Irisson E, Hémon Y, Pauly V, Parratte S, Argenson JN, Kerbaul F. Tranexamic acid reduces blood loss and financial cost in primary total hip and knee replacement surgery. Orthop Traumatol Surg Res. 2012;98(4):477-83.
Downloads
Published
How to Cite
Issue
Section
